Ontario Welcomes Biosimilar Switching Policy Following Extended Campaign
Industry Has Urged Province To Implement Switching Policy For Over A Year
Ontario has joined several other Canadian provinces and territories by implementing a biosimilar switching policy for Ontarians taking biologic drugs.
You may also be interested in...
Newfoundland and Labrador has become the ninth jurisdiction in Canada to implement a biosimilar switching policy for patients enrolled on its public health program.
Prepare for all the biggest industry actions and events in March 2023 with Generics Bulletin’s monthly column.
Biosimilars Canada has renewed its call for Ontario to adopt a biosimilar switching policy in line with other Canadian provinces and territories, suggesting that Ontario alone could save CAD147m annually through such a scheme.